Literature DB >> 21872946

Prognostic value of neutrophil gelatinase-associated lipocalin in acute heart failure.

Margarida Alvelos1, Patrícia Lourenço, Carla Dias, Marta Amorim, Joana Rema, Ana Bento Leite, João Tiago Guimarães, Pedro Almeida, Paulo Bettencourt.   

Abstract

BACKGROUND: The identification of patients at risk for worse outcome is still a challenge. We hypothesized that cystatin C, a marker of renal function, and neutrophil gelatinase-associated lipocalin (NGAL), a marker of acute renal injury, would have a role in the prognostic stratification of these patients.
METHODS: We prospectively evaluated 121 patients admitted for acute HF. Serum NGAL and cystatin C levels were measured on the first morning after admission. The outcome measures used were the occurrence of death from all causes, and the combined endpoint defined as the first occurrence of either death or hospital admission. Patients were followed for up to 3 months.
RESULTS: The variables associated with a higher occurrence of death in a univariate approach were older age and higher levels of BNP, cystatin C and NGAL, and those associated with the occurrence of the combined endpoint were older age, Diabetes mellitus, lower GFR, type 1 cardio-renal syndrome, BNP, cystatin C and NGAL. BNP and NGAL remained independent predictors of the occurrence of both all-cause death and the combined endpoint. NGAL levels in the 75th percentile (>167.5 ng/mL) were associated with a 2.7-fold increase in the risk of death and a 2.9-fold increase in the risk of the first occurrence of either death or hospitalization.
CONCLUSIONS: Serum NGAL, a marker of acute renal injury, is an independent predictor of worse short term prognosis in patients with acute HF. This suggests a role of renal damage, apart from renal function, in the prognosis of these patients.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21872946     DOI: 10.1016/j.ijcard.2011.07.080

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  29 in total

1.  Management of the cardiorenal syndrome in acute heart failure.

Authors:  Valentina Lazzarini; G Michael Felker
Journal:  Curr Treat Options Cardiovasc Med       Date:  2012-08

Review 2.  Synthesizing Markers of Kidney Injury in Acute Decompensated Heart Failure: Should We Even Keep Looking?

Authors:  Alexander S Manguba; Xavier Vela Parada; Steven G Coca; Anuradha Lala
Journal:  Curr Heart Fail Rep       Date:  2019-12

Review 3.  Clinical use of novel biomarkers in heart failure: towards personalized medicine.

Authors:  Daniela Schmitter; Gadi Cotter; Adriaan A Voors
Journal:  Heart Fail Rev       Date:  2014-05       Impact factor: 4.214

4.  Elevated urinary neutrophil gelatinase-associated lipocalcin after acute heart failure treatment is associated with worsening renal function and adverse events.

Authors:  Sean P Collins; Kimberly W Hart; Christopher J Lindsell; Gregory J Fermann; Neal L Weintraub; Karen F Miller; Susan N Roll; Matthew I Sperling; Douglas B Sawyer; Alan B Storrow
Journal:  Eur J Heart Fail       Date:  2012-06-25       Impact factor: 15.534

5.  The Number of GT(n) Repeats in the Hemeoxygenase-1 Gene Promoter is Increased in Pediatric Heart Failure but is Unrelated to Renal, Antioxidant and Anti-inflammatory Markers.

Authors:  Sherif Sayed; Naglaa K Idriss; Andrew Blann; Hayam G Sayyed; D M Raafat; Doaa Fouad; M S K Tawfeek
Journal:  Pediatr Cardiol       Date:  2015-03-31       Impact factor: 1.655

6.  Urinary [TIMP-2] × [IGFBP7] for risk prediction of acute kidney injury in decompensated heart failure.

Authors:  Moritz Schanz; Jing Shi; Christoph Wasser; Mark Dominik Alscher; Martin Kimmel
Journal:  Clin Cardiol       Date:  2017-03-10       Impact factor: 2.882

Review 7.  Decompensated Heart Failure and Renal Failure: What Is the Current Evidence?

Authors:  Agata Bielecka-Dabrowa; Breno Godoy; Joerg C Schefold; Michael Koziolek; Maciej Banach; Stephan von Haehling
Journal:  Curr Heart Fail Rep       Date:  2018-08

8.  Serum neutrophil gelatinase-associated lipocalin is associated with cardiovascular events in patients with chronic kidney disease.

Authors:  Yalcin Solak; Mahmut Ilker Yilmaz; Dimitrie Siriopol; Mutlu Saglam; Hilmi Umut Unal; Halil Yaman; Mahmut Gok; Hakki Cetinkaya; Abduzhappar Gaipov; Tayfun Eyileten; Sebahattin Sari; Ali Osman Yildirim; Halil Zeki Tonbul; Suleyman Turk; Adrian Covic; Mehmet Kanbay
Journal:  Int Urol Nephrol       Date:  2015-10-26       Impact factor: 2.370

9.  Serum neutrophil gelatinase-associated lipocalin concentration reflects severity of coronary artery disease in patients without heart failure and chronic kidney disease.

Authors:  Mikako Katagiri; Masao Takahashi; Kent Doi; Masahiro Myojo; Arihiro Kiyosue; Jiro Ando; Yasunobu Hirata; Issei Komuro
Journal:  Heart Vessels       Date:  2015-11-27       Impact factor: 2.037

Review 10.  Cardiac Biomarkers in Advanced Heart Failure: How Can They Impact Our Pre-transplant or Pre-LVAD Decision-making.

Authors:  Imo Ebong; Sula Mazimba; Khadijah Breathett
Journal:  Curr Heart Fail Rep       Date:  2019-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.